APL 5125
Alternative Names: APL-5125Latest Information Update: 26 Jul 2024
At a glance
- Originator Apollo Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 18 Jun 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT06399757)
- 06 May 2024 Apollo Therapeutics plans phase-I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in May 2024 (PO, Capsule) (NCT06399757),
- 06 May 2024 Preclinical trials in Solid tumours in United Kingdom (PO) (NCT06399757)